Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

Oncolytics Biotech has aligned with the FDA on the design of a pivotal study for pelareorep in first-line pancreatic cancer. The Phase 3 trial will evaluate pelareorep in combination with chemotherapy, with or without a checkpoint inhibitor, compared to chemotherapy alone. The study will be the only current registration trial with an immunotherapy in first-line pancreatic cancer and is expected to launch in H1 2026.